Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intravesical Therapy – BCG and Beyond

Intravesical Therapy – BCG and Beyond Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette–Guérin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bladder Cancer IOS Press

Intravesical Therapy – BCG and Beyond

Download PDF
8 pages

Loading next page...
 
/lp/ios-press/intravesical-therapy-bcg-and-beyond-01sw0Tx0tW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2019 © 2019 – IOS Press and the authors. All rights reserved
ISSN
2352-3727
eISSN
2352-3735
DOI
10.3233/BLC-180198
Publisher site
See Article on Publisher Site

Abstract

Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette–Guérin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.

Journal

Bladder Cancer – IOS Press

Published: Jan 1, 2019

References

  • Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
    Morales
  • Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma
    Burnand
  • Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
    Sylvester
  • Maintenance BCG Immunotherapy in Recurrent Ta, T1 and Carcinoma in situ Transitional Cell Carcinoma: A Randomized Southwest Oncology Group Study
    Lamm
  • Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma
    Friedrich
  • A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer
    Grossman
  • Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer
    Lamm
  • A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder
    Lamm
  • Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study
    Lamm
  • Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
    Sylvester
  • Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer
    Spencer
  • Bacillus Calmette-Guerin immunotherapy for genitourinary cancer
    Gandhi
  • Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
    Sylvester
  • Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors
    Palou
  • Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: Can it predict the optimal number of instillations?
    de Reijke
  • Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer
    Patel
  • Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification
    Sjodahl
  • Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
    Robertson
  • A molecular taxonomy for urothelial carcinoma
    Sjodahl
  • Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
    Hedegaard
  • Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies
    Hafner
  • Tumors of the urinary bladder: A clinico-pathological analysis of over 2500 specimens and biopsies
    Melicow
  • A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma
    Patschan
  • Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study
    Dyrskjot
  • Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder
    Fukui
  • Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: A longer followup result
    Sekine
  • A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer
    Chen
  • Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
    Lightfoot
  • Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
    Cockerill
  • Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
    Steinberg
  • Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
    Milbar
  • MP15-13 A Phase I trial for the use of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG-refractory non-muscle invasive urothelial carcinoma of the bladder
    DeCastro
  • SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin
    Skinner
  • Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy
    Barlow
  • Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
    Shore
  • Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
    Huang
  • MP15-12 PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAÏVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
    Rosser